Randhawa Simrat
EVP, Head of R&D
Randhawa Simrat has filed 4 SEC Form 4 filings (27 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Sep 3, 2026.
On the most recent filing, Randhawa Simrat is listed as EVP, Head of R&D at Dianthus Therapeutics, Inc. Inside the rolling window, Randhawa Simrat reported no open-market purchases and 5 open-market sales totaling $15.0M in DNTH. The largest disclosed transaction in the window is a sale of 109,031 DNTH shares on Nov 14, 2025, worth $4.2M.
Companies traded
Other insiders at DNTH
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$15.0M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Randhawa Simrat made?
Randhawa Simrat has filed 4 SEC Form 4 filings (27 transaction rows) across 1 company since 2025.
Which companies does Randhawa Simrat trade?
Randhawa Simrat has filed SEC Form 4 disclosures for 1 company, including DNTH.
When was Randhawa Simrat's most recent SEC Form 4 filing?
Randhawa Simrat's most recent SEC Form 4 filing on Tracefour is dated Sep 3, 2026.
What is Randhawa Simrat's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Randhawa Simrat is listed as EVP, Head of R&D.
What is Randhawa Simrat's total buy and sell value in the current window?
Inside the rolling retention window, Randhawa Simrat bought $0 and sold $15.0M based on SEC Form 4 filings.
What was Randhawa Simrat's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 109,031 DNTH shares on 2025-11-14, worth $4.2M, per SEC Form 4 filings.